VAXNEUVANCE
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $80,601 | 561 | 478 |
| 2023 | $244,172 | 1,331 | 1,024 |
| 2022 | $63,812 | 634 | 563 |
| 2021 | $229.52 | 13 | 13 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $218,045 | 99 | 56.1% |
| Food and Beverage | $95,501 | 2,158 | 24.6% |
| Travel and Lodging | $61,095 | 218 | 15.7% |
| Unspecified | $13,114 | 2 | 3.4% |
| Education | $1,059 | 62 | 0.3% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| STUDY NAME#Response to guideline-concordant pneumococcal vaccination strategy in cardiac transplant candidates and recipients | Merck Sharp & Dohme LLC | $6,654 | 0 |
| Response to guideline-concordant pneumococcal vaccination strategy in cardiac transplant candidates and recipients | Merck Sharp & Dohme LLC | $6,460 | 0 |
Top Doctors Receiving Payments for VAXNEUVANCE — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Pediatrics | Santa Ana, CA | $143.22 | 2 |
| , M.D | Pediatrics | San Juan, PR | $141.28 | 2 |
| , MD | Pediatric Pulmonology | San Juan, PR | $140.31 | 5 |
| , M.D | Pediatrics | Anaheim, CA | $138.26 | 2 |
| , MD | Pediatrics | Corona, NY | $136.84 | 2 |
| , MD | General Acute Care Hospital | Bronx, NY | $134.18 | 1 |
| , M.D | Pediatrics | El Paso, TX | $134.18 | 1 |
| , MD | Pediatrics | Bronx, NY | $134.18 | 1 |
| , FNP | Family | New York, NY | $134.18 | 1 |
| , MD | Pediatric Emergency Medicine | New York, NY | $134.18 | 1 |
| , MD | Pediatrics | Bronx, NY | $134.18 | 1 |
| , MD | Pediatrics | New York, NY | $134.18 | 1 |
| , M.D | Adolescent Medicine | Bronx, NY | $134.18 | 1 |
| , M.D | Pediatrics | Lares, PR | $134.10 | 3 |
| Carlos Lopez | — | Phoenix, AZ | $133.97 | 2 |
| , DO | Pediatric Endocrinology | Columbus, OH | $128.68 | 1 |
| , M. D | Pediatrics | West New York, NJ | $128.68 | 1 |
| , M.D | Hospice and Palliative Medicine | West New York, NJ | $128.68 | 1 |
| , D.O | Pediatrics | Newark, NJ | $128.68 | 1 |
| , RN, CPNP | Pediatrics | Hackensack, NJ | $128.68 | 1 |
| , MD | Pediatrics | North Bergen, NJ | $128.68 | 1 |
| , M.D | Pediatrics | West New York, NJ | $128.68 | 1 |
| , MD | Pediatrics | Springfield, NJ | $128.68 | 1 |
| , MD | Pediatrics | Queens Village, NY | $125.00 | 1 |
| , FNP-C, CPNP | Family | San Diego, CA | $125.00 | 1 |
Manufacturing Companies
- Merck Sharp & Dohme LLC $388,584
- Merck Sharp & Dohme Corporation $229.52
Product Information
- Type Biological
- Total Payments $388,814
- Total Doctors 1,929
- Transactions 2,539
About VAXNEUVANCE
VAXNEUVANCE is a biological associated with $388,814 in payments to 1,929 healthcare providers, recorded across 2,539 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2021 to 2024. In 2024, $80,601 was paid across 561 transactions to 478 doctors.
The most common payment nature for VAXNEUVANCE is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($218,045, 56.1% of total).
VAXNEUVANCE is associated with 2 research studies, including "STUDY NAME#Response to guideline-concordant pneumococcal vaccination strategy in cardiac transplant candidates and recipients" ($6,654).